Related Experiment Videos
A rapid screening method for a single nucleotide polymorphism (SNP) in the human MOR gene
S Grösch1, E Niederberger, J Lötsch
1pharmazentrum frankfurt, Klinikum der Johann Wolfgang Goethe-Universität Frankfurt, Theodor Stern Kai7, 60590 Frankfurt/Main, Germany.
British Journal of Clinical Pharmacology
|December 12, 2001
Summary
A new FRET-PCR method accurately detects the A118G single nucleotide polymorphism (SNP) in the mu-opioid receptor (MOR) gene. This rapid technique is suitable for clinical settings and population screening of drug treatment variability.
Area of Science:
- Pharmacogenetics
- Molecular Biology
- Genetics
Background:
- Genetic variations, such as single nucleotide polymorphisms (SNPs), influence drug treatment variability.
- The mu-opioid receptor (MOR) gene SNP at position 118 has been implicated as a potential risk factor for variable drug responses.
Purpose of the Study:
- To develop a rapid and reliable method for detecting the A118G SNP in the human MOR gene.
- To establish a clinically applicable assay for genetic screening related to drug treatment variability.
Main Methods:
- Utilized fluorescence resonance energy transfer (FRET)-PCR combined with melting curve analysis.
- Validated FRET-PCR results using sequencing and restriction-fragment length polymorphism (RFLP) methods.
Main Results:
- Successfully discriminated between wild-type and mutated MOR alleles based on distinct melting peak temperatures (69.8°C and 63.8°C, respectively).
- Screening of 100 subjects revealed an allelic distribution: 79% homozygous wild-type, 20% heterozygous, and 0.9% homozygous mutated.
Conclusions:
- The developed FRET-PCR protocol provides a fast and dependable method for detecting the human MOR gene A118G polymorphism.
- This assay is suitable for population-level genetic screening, aiding in understanding drug treatment variability.